Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019
October 02 2019 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, today announces
top-line revenue guidance for the quarter ended September 30, 2019.
Alimera expects to report consolidated net revenue for the third
quarter of 2019 exceeding $12.8 million. This compares to $10.9
million for the second quarter of 2019 and $11.1 million in the
third quarter of 2018.
“We are pleased to pre-release our global revenue expectation
for the third quarter of 2019. In the U.S. in the third quarter we
saw sequential growth over the second quarter, which supports our
belief that we have successfully addressed the domestic sales force
issues we experienced in the first half of the year,” said Rick
Eiswirth, President and CEO of Alimera. “Our international sales
segment continues to exhibit strong growth, as we further penetrate
into existing territories with ILUVIEN®’s two approved indications,
diabetic macular edema and non-infectious posterior uveitis. We
look forward to sharing more detail on these top line results and
other performance metrics on our third quarter earnings call at the
end of this month.”
Alimera will report its complete third quarter 2019 earnings
results on October 29, 2019, after the close of the market, with a
conference call to be held on October 30, 2019 at 9:00am Eastern
time.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, Alimera’s expectations
regarding its revenue for the third quarter of 2019 and its belief
that it has successfully addressed its domestic sales force issues.
Such forward-looking statements are based on current expectations
and involve inherent risks and uncertainties, including factors
that could delay, divert or change either of them, and could cause
actual results to differ materially from those projected in its
forward-looking statements. Meaningful factors that could cause
actual results to differ include, but are not limited to, (a) final
accounting adjustments in Alimera’s revenue for the third quarter
of 2019 may cause the actual reported amount to be less than stated
above; (b) unexpected departures of members of Alimera’s sales
force, or underperformance of that sales force, could occur; (c)
Alimera’s domestic and international revenue could decline due to a
reduction in end user demand, unanticipated competition, regulatory
issues, or other unexpected circumstances; and (d) other factors
discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of Alimera’s Annual Report on Form 10-K for the year ended December
31, 2018, which is on file with the Securities and Exchange
Commission and available on its website at http://www.sec.gov.
For press
inquiries:Jules Abrahamfor Alimera Sciences
917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciences scottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024